Market cap
$113.47B
Shares out
2.44B
52-week range65% up the range
$39.07$50.60

What is the latest news on SNY stock?

SNY rose 1.01% to $46.52 on Nov 20, 2026. No SNY story in the last two days; the most recent is below.

FDAago
FDA Approval for INFILBRAY issued to GENZYME CORP A SANOFI CO

Submission status for GENZYME CORP A SANOFI CO's drug INFILBRAY (ORIG-1) with active ingredient VENGLUSTAT has changed to 'Approval' on 11/18/2026. Application Category: NDA, Application Number: 221144, Application Classification: Type 1 - New Molecular Entity

All SNY news
Price$46.52+1.41 (+3.11%)
2026-08-202026-11-20

When does Sanofi report earnings?

The latest Sanofi earnings release came out on Jun 2, 2025: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology. Before that, Sanofi reported on May 13, 2024.

SNY earnings history

Who owns the most SNY stock?

Dodge & Cox was the largest reported holder of SNY at the end of Q2 2026, with 28,088,274 shares worth $1.2 billion. Next came Morgan Stanley ($456.6 million) and Fisher Asset Management, LLC ($453.4 million). In all, 715 institutions reported $8.1 billion of SNY in their 13F filings.

All SNY fund holders

Financial highlights

Full financials
Revenue, FY2025
€43.63B
Revenue growth
+6.2%
Net income, FY2025
€7.81B
Net margin
17.9%
Free cash flow, FY2025
€7.21B
Cash
€7.66B

For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.

Latest news

25 items

Hiring

Nov 22, 2026

Sanofi lists 1,426 open roles on its careers site as of Nov 22, 2026.

Open roles
1,426

Counted daily from Sanofi's careers site.

SNY rankings

News · 26 weeks51+43%
2026-05-31: 22026-06-07: 22026-06-14: 02026-06-21: 32026-06-28: 52026-07-05: 12026-07-12: 22026-07-19: 02026-07-26: 52026-08-02: 32026-08-09: 22026-08-16: 02026-08-23: 12026-08-30: 02026-09-06: 42026-09-13: 22026-09-20: 02026-09-27: 22026-10-04: 12026-10-11: 22026-10-18: 12026-10-25: 32026-11-01: 12026-11-08: 72026-11-15: 22026-11-22: 0
2026-05-312026-11-22
Mix2690d
  • Other19(73%)
  • SEC Filings4(15%)
  • Analyst3(12%)
Activity · 52 weeks10480 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Our reporting on SNY

Sanofi (SNY) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 13 wire items for SNY, including 10 press releases and news items, 2 SEC filings and 1 analyst rating. The most recent was published Nov 19, 2026.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. It also has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration with TrialSpark Inc. to execute clinical research studies in the areas of chronic obstructive pulmonary disease. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

SNY FAQ

10 questions
  • What does Sanofi do?
    Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis...
  • What is SNY revenue?
    Sanofi (SNY) reported €43.63B of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 6.2% from the year before.
  • Is SNY profitable?
    Yes. Sanofi earned €7.81B in net income for fiscal 2025 (ended Dec 31, 2025), a net margin of 17.9%.
  • How much cash and debt does SNY have?
    Sanofi reported €7.66B in cash and cash equivalents and €18.59B of debt on its most recent balance sheet in SEC filings.
  • Is Sanofi (SNY) hiring?
    Sanofi lists 1,426 open roles on its careers site as of Nov 22, 2026.
  • Where does SNY stock trade?
    Sanofi (SNY) is listed on NASDAQ.
  • What sector and industry is SNY in?
    Sanofi operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • What are analysts saying about SNY?
    Across the last 8 analyst actions on Sanofi, there was 1 upgrade and 4 downgrades. The most recent action was from BNP Paribas Exane: Outperform on 2026-11-09. Recent price targets cluster around $50.00.
  • What companies are similar to SNY?
    Notable peers in the same industry include JNJ (Johnson & Johnson), MRK (Merck & Company Inc.), PFE (Pfizer Inc.), LLY (Eli Lilly and Company), NVO (Novo Nordisk A/S). Compare SNY side-by-side with any of them on Quantisnow.
  • How can I track SNY on Quantisnow?
    Quantisnow aggregates Sanofi's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SNY to receive live email and push alerts on every new disclosure.

Is something on this page wrong, or out of date? Request a change